Capital International Ltd. CA Sells 18,298 Shares of Boston Scientific Corporation $BSX

Capital International Ltd. CA lowered its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 8.2% in the 3rd quarter, Holdings Channel.com reports. The firm owned 203,591 shares of the medical equipment provider’s stock after selling 18,298 shares during the quarter. Capital International Ltd. CA’s holdings in Boston Scientific were worth $19,877,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. Gerber Kawasaki Wealth & Investment Management boosted its position in shares of Boston Scientific by 3.8% during the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock worth $291,000 after acquiring an additional 99 shares during the last quarter. Crown Wealth Group LLC increased its position in shares of Boston Scientific by 4.7% during the 3rd quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock valued at $218,000 after purchasing an additional 100 shares during the last quarter. Sound View Wealth Advisors Group LLC increased its position in Boston Scientific by 3.9% during the second quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock valued at $294,000 after acquiring an additional 103 shares during the last quarter. Cary Street Partners Investment Advisory LLC boosted its stake in shares of Boston Scientific by 5.1% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock worth $206,000 after purchasing an additional 103 shares during the period. Finally, Scotia Capital Inc. boosted its position in shares of Boston Scientific by 0.7% during the second quarter. Scotia Capital Inc. now owns 15,093 shares of the medical equipment provider’s stock valued at $1,621,000 after buying an additional 104 shares during the period. 89.07% of the stock is owned by institutional investors.

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. UBS Group reduced their target price on Boston Scientific from $140.00 to $120.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Needham & Company LLC reduced their price target on shares of Boston Scientific from $121.00 to $97.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. JPMorgan Chase & Co. lowered their target price on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Finally, The Goldman Sachs Group set a $99.00 price target on Boston Scientific in a report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $108.36.

Boston Scientific Stock Up 0.7%

Boston Scientific stock opened at $71.88 on Tuesday. The firm has a market capitalization of $106.66 billion, a P/E ratio of 37.05, a P/E/G ratio of 1.00 and a beta of 0.69. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a twelve month low of $69.52 and a twelve month high of $109.50. The stock’s fifty day simple moving average is $84.55 and its 200-day simple moving average is $94.24.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Company actions that may support the share price: Boston Scientific negotiated a new $3.0 billion revolving credit facility (matures 2031), expanded its share‑repurchase authorization to $5.0 billion, and added two senior healthcare/finance leaders to the board — moves that can bolster liquidity and signal confidence in capital returns. Is Boston Scientific (BSX) Balancing Buybacks and Litigation or Masking Deeper Electrophysiology Risks?
• Neutral Sentiment: Options activity: traders bought ~23,040 put contracts on Monday — roughly a 27% increase vs. typical daily put volume — indicating elevated hedging or bearish interest but not a definitive directional signal by itself.
• Negative Sentiment: Legal and regulatory risk escalating: multiple law firms (Rosen, Levi & Korsinsky, Robbins, Bronstein, Schall, Faruqi & Faruqi) have filed or announced investigations and class actions on behalf of BSX investors covering the July 23, 2025–Feb 3, 2026 period; lead‑plaintiff deadlines have been set (May 4, 2026 in several notices). The suits and media coverage cite a Class I recall of the AXIOS Stent & Delivery System, a federal probe of disclosures/product safety, and allegations of misleading statements about the U.S. electrophysiology business — risks that could lead to settlements, fines, or reputational damage and weigh on earnings and cash flow. Shareholders of Boston Scientific Corporation Should Contact Levi & Korsinsky Boston Scientific Recall And Lawsuits Test Earnings Power And Capital Plans

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.